NO20003804L - FremgangsmÕte for fremstilling av absorberbare mikropartikler - Google Patents

FremgangsmÕte for fremstilling av absorberbare mikropartikler

Info

Publication number
NO20003804L
NO20003804L NO20003804A NO20003804A NO20003804L NO 20003804 L NO20003804 L NO 20003804L NO 20003804 A NO20003804 A NO 20003804A NO 20003804 A NO20003804 A NO 20003804A NO 20003804 L NO20003804 L NO 20003804L
Authority
NO
Norway
Prior art keywords
microparticles
making absorbable
microparticle
bound
absorbable microparticles
Prior art date
Application number
NO20003804A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003804D0 (no
Inventor
Thomas Ciaran Loughman
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Publication of NO20003804D0 publication Critical patent/NO20003804D0/no
Publication of NO20003804L publication Critical patent/NO20003804L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20003804A 1998-01-29 2000-07-25 FremgangsmÕte for fremstilling av absorberbare mikropartikler NO20003804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE980054 1998-01-29
PCT/IE1999/000007 WO1999038535A1 (en) 1998-01-29 1999-01-25 Process for making absorbable microparticles

Publications (2)

Publication Number Publication Date
NO20003804D0 NO20003804D0 (no) 2000-07-25
NO20003804L true NO20003804L (no) 2000-09-20

Family

ID=11041696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003804A NO20003804L (no) 1998-01-29 2000-07-25 FremgangsmÕte for fremstilling av absorberbare mikropartikler

Country Status (17)

Country Link
US (1) US6555156B1 (xx)
EP (1) EP1051194B9 (xx)
JP (1) JP2002501907A (xx)
CN (1) CN1289255A (xx)
AR (1) AR014069A1 (xx)
AT (1) ATE240121T1 (xx)
AU (1) AU740493B2 (xx)
CA (1) CA2318513A1 (xx)
DE (1) DE69907870T2 (xx)
DK (1) DK1051194T3 (xx)
ES (1) ES2194437T3 (xx)
HU (1) HUP0102373A2 (xx)
IL (1) IL137349A0 (xx)
NO (1) NO20003804L (xx)
PL (1) PL342135A1 (xx)
PT (1) PT1051194E (xx)
WO (1) WO1999038535A1 (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
CA2510199A1 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
CA2552758A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
EP1703915A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド 心脈管および腎臓の適応症のための制御放出cgrp送達組成物
US7578951B2 (en) * 2004-01-27 2009-08-25 Hewlett-Packard Development Company, L.P. Method of making microcapsules utilizing a fluid ejector
US20060084628A1 (en) 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
WO2010009291A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8968787B2 (en) * 2010-05-24 2015-03-03 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
EP3370694A1 (en) 2015-11-06 2018-09-12 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPH0778017B2 (ja) 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JPH07503700A (ja) * 1991-01-03 1995-04-20 アルカーメス コントロールド セラピューティックス, インコーポレイテッド カチオン生体ポリマーによるタンパク質の安定化
US5366756A (en) 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
WO1995003356A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides

Also Published As

Publication number Publication date
AU740493B2 (en) 2001-11-08
CN1289255A (zh) 2001-03-28
DE69907870T2 (de) 2004-03-04
IL137349A0 (en) 2001-07-24
AR014069A1 (es) 2001-01-31
US6555156B1 (en) 2003-04-29
ES2194437T3 (es) 2003-11-16
DE69907870D1 (de) 2003-06-18
EP1051194B9 (en) 2003-11-05
HUP0102373A2 (hu) 2001-10-28
NO20003804D0 (no) 2000-07-25
PL342135A1 (en) 2001-05-21
AU2296699A (en) 1999-08-16
ATE240121T1 (de) 2003-05-15
CA2318513A1 (en) 1999-08-05
EP1051194A1 (en) 2000-11-15
JP2002501907A (ja) 2002-01-22
EP1051194B1 (en) 2003-05-14
PT1051194E (pt) 2003-09-30
WO1999038535A1 (en) 1999-08-05
DK1051194T3 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
NO20003804L (no) FremgangsmÕte for fremstilling av absorberbare mikropartikler
LUC00074I2 (en) Method for controlling the activity of immunologically functional molecule
DE69830574D1 (de) Verbesserte verfahren zur herstellung von vernetzt verbrückten macropolycyclen
EP1526454A3 (en) Application identity for software products
BR0007152B1 (pt) processo para produzir catalisador revestido obtido pelo revestimento da composição de componente cataliticamente ativo em um veìculo inativo.
ZA965108B (en) Process for preparing reduced odor and improved brightness individualized, polycarboxylic acid crosslinked fibers.
DE69935547D1 (de) Mit Vertiefungen versehner, optischer Verteiler für Fahrzeug-Beleuchtungssystem
DE50011459D1 (de) Verfahren und vorrichtung zur clusterfragmentation
DE60034566D1 (de) Peptidakzeptor ligationsverfahren
WO2006138379A3 (en) Resolving resource allocation conflicts for access terminals
ATE205866T1 (de) Hydrophile, hochquellfähige hydrogele
DE59811911D1 (de) Verfahren zur Herstellung von stabilen, feinteiligen Polymerdispersionen
WO2003024021A3 (de) Skalierbares peer-to-peer-netzwerk mit einem verzeichnisdienst
ES2193102T3 (es) Compuestos de imidocromo en sistemas catalizadores para la polimerizacion de olefinas.
AU1091899A (en) Methods of making a molecular sieve containing catalyst
DE60041452D1 (de) CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN
DE59803734D1 (de) Verfahren zur herstellung von halogenfreiem, reaktivem polyisobuten
DE69613384D1 (de) Verfahren zur hydrocyanierung von organischen, ethylenisch ungesättigten verbindungen
WO2001000875A3 (en) Novel methods and products for arrayed microsphere analysis
BR9609961A (pt) Dispositivo para o desprendimento da ancoragem de um pedal da estrutura de um veículo automotivo
NO975791D0 (no) Fremgangsmåte for fremstilling av spraybare, kationiske biopolymerer
TR199800692A3 (tr) Kalsiyum borat üretilmesine mahsus yöntem.
WO2002076032A3 (de) Verfahren und vorrichtung zur erstellung eines zeitplans der übermittlung von nachrichten auf einem bussystem
NO960510L (no) Fremgangsmåte for å fremstille små, diskrete, sfæriske addukter
BRPI9808642B8 (pt) processo para preparar eprosartan a partir de 2-n-butil-4-formilidazol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application